Press Releases

All Releases
View Summary BG Medicine, Inc. Prices $10.0 Million Public Offering of Common Stock
Apr 3, 2014
PDF 19.4 KB Add to Briefcase
View Summary BG Medicine, Inc. Announces Proposed Public Offering of Common Stock
Apr 2, 2014
PDF 19.0 KB Add to Briefcase
View Summary Publication Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction of Near-Term Rehospitalization in Patients With Heart Failure
Mar 25, 2014
PDF 17.8 KB Add to Briefcase
View Summary BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy
Mar 20, 2014
PDF 15.6 KB Add to Briefcase
View Summary BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results
Mar 20, 2014
PDF 27.2 KB Add to Briefcase
View Summary BG Medicine Announces Fiscal Year 2013 Financial Results Release Date and Conference Call Information
Mar 13, 2014
PDF 13.4 KB Add to Briefcase
View Summary BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease
Mar 12, 2014
PDF 16.8 KB Add to Briefcase
View Summary BG Medicine Compliant With NASDAQ Listing Requirements
Mar 11, 2014
PDF 11.9 KB Add to Briefcase
View Summary BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers
Mar 10, 2014
PDF 17.8 KB Add to Briefcase
View Summary Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study
Jan 28, 2014
PDF 18.0 KB Add to Briefcase
View Summary BG Medicine to Transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ Extension
Jan 27, 2014
PDF 16.1 KB Add to Briefcase
View Summary BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test
Dec 10, 2013
PDF 17.7 KB Add to Briefcase
View Summary Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure
Nov 19, 2013
PDF 17.6 KB Add to Briefcase
View Summary BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer
Nov 14, 2013
PDF 14.5 KB Add to Briefcase
View Summary BG Medicine Reports 2013 Third Quarter Financial Results
Nov 6, 2013
PDF 30.7 KB Add to Briefcase
View Summary SilverStaff Clinical Laboratories to Offer BGM Galectin-3(R) Test
Nov 6, 2013
PDF 30.3 KB Add to Briefcase
View Summary BG Medicine to Announce Third Quarter 2013 Financial Results and Host Conference Call on Wednesday, November 6, 2013
Oct 30, 2013
PDF 16.1 KB Add to Briefcase
View Summary BG Medicine Announces Preliminary Decision by CMS on Reconsideration of Reimbursement for BGM Galectin-3 Test
Sep 30, 2013
PDF 18.5 KB Add to Briefcase
View Summary BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General Hospital Demonstrating Predictive Value of Adverse Outcomes in Heart Failure Patients
Sep 23, 2013
PDF 21.1 KB Add to Briefcase
View Summary BG Medicine, Inc. Announces Schedule of Events Related to Galectin-3 at the 17th Annual Scientific Meeting of the Heart Failure Society of America
Sep 19, 2013
PDF 17.3 KB Add to Briefcase
Showing 1-20 of 176 Page: 1 2 3 4 5 ... 9  Next 20
Add to Briefcase = add release to Briefcase